摘要:
A method and apparatus are disclosed for treating mitral or tricuspid regurgitation with electrical stimulation. By providing pacing stimulation to a selected region of the left ventricle, such as one in proximity to the mitral valve apparatus in a manner which pre-excites the region during early ventricular systole, a beneficial effect is obtained which can prevent or reduce the extent of mitral regurgitation.
摘要:
A method and apparatus are disclosed for treating mitral or tricuspid regurgitation with electrical stimulation. By providing pacing stimulation to a selected region of the left ventricle, such as one in proximity to the mitral valve apparatus or papillary muscles in a manner that pre-excites the region during early ventricular systole, a beneficial effect is obtained which can prevent or reduce the extent of mitral regurgitation.
摘要:
An implantable cardiac rhythm management (CRM) device delivers a chronic therapy while detecting an ischemic state. When the ischemic state indicates the occurrence of an ischemic event, the implantable CRM device delivers a post-ischemia therapy. The post-ischemia therapy and the chronic therapy are adjusted using feedback control with the ischemic state and parameters indicative of the effectiveness of the post-ischemic therapy and the effectiveness of the chronic therapy as inputs.
摘要:
A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid to glucose. One example of such a system includes an implantable device detecting an ischemia and a transdermal drug delivery device delivering a drug when an ischemic condition is detected. Another example of such a system includes one or more implantable devices detecting a predefined change in cardiac metabolic level and delivering a drug when the change is detected. Such systems are applied to treat, for example, patients suffering ischemia and/or heart failure and patients having suffered myocardial infarction.
摘要:
A drug delivery system detects a cardiac condition indicative of a need for increasing a cardiac metabolic level and, in response, releases a drug into tissue or blood to shift a source of metabolically synthesized energy fueling cardiac contraction from fatty acid to glucose. One example of such a system includes an implantable device detecting an ischemia and a transdermal drug delivery device delivering a drug when an ischemic condition is detected. Another example of such a system includes one or more implantable devices detecting a predefined change in cardiac metabolic level and delivering a drug when the change is detected. Such systems are applied to treat, for example, patients suffering ischemia and/or heart failure and patients having suffered myocardial infarction.
摘要:
A method for treating patients after a myocardial infarction which includes pacing therapy is disclosed. A cardiac rhythm management device is configured to deliver pre-excitation pacing to one or more sites in proximity to an infarcted region of the ventricular myocardium. Such pacing acts to minimize the remodeling process to which the heart is especially vulnerable immediately after a myocardial infarction.
摘要:
A method and apparatus for linear stimulation of the heart to resynchronize contraction for improved hemodynamic benefit. Linear stimulation may be accomplished using a linear source, which may comprise an elongated electrode or plurality of electrodes arranged so as to linearly stimulate the heart. A linear source may be coupled to the left ventricle, and one or more additional electrodes may be positioned so as to stimulate a separate region of the left ventricle or one or more additional chambers of the heart as well. Application of an electrical stimulus by the linear source may function to stimulate a larger region of the heart, thereby enhancing the resynchronization effect as well as providing other hemodynamic benefits.
摘要:
Implantable devices are configured to be positioned in or near the heart and to carry and deliver an anti-apoptotic drug to a treatment site in or near the heart. The implantable devices include, but are not limited to, leads, stents, heart valves, atrial septal defect devices, cardiac patches and ventricular restraint devices. Depending on the composition of the device, the drug may be carried by the device through a coating applied to the device, or may be included in the device during the device manufacturing process. The drug may also be included in microparticles, such a microspheres, that are delivered locally through a conduit, such as a catheter.
摘要:
An ultrasonic implantable device includes an ultrasonic sensor having a plurality of transducers. The sensor is configured for mounting to a vessel wall. A first of the transducers directs sound waves in a direction at least partially upstream or downstream in the vessel. A second of the transducers directs sound waves in a radial direction through an interior of the vessel against a sidewall of the vessel. The sensor monitors a change in frequency of the sound waves from the first transducer to determine a fluid velocity in the vessel. The sensor also monitors a reflection time of the sound waves from the second transducer that return from the sidewall to determine an internal diameter of the vessel. The determined fluid velocity and vessel diameter can be used to determine a volumetric flow rate of the fluid in the vessel.
摘要:
A method includes mounting an anchor member to a surface of a heart, the anchor member having a tension member coupled to the anchor member, advancing a lead body along the tension member, the lead body including a plurality of electrodes disposed along the lead body, identifying an MI region of the heart, positioning the plurality of electrodes at or near the MI region, affixing the tension member to the lead body to hold the electrodes in position, and delivering pulses through the plurality of electrodes to the heart.